Navigation Links
FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics' Resubmitted Pixantrone New Drug Application
Date:12/6/2011

sed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that accelerated approval by the FDA of pixantrone may not occur, that CTI may not be able to address satisfactorily the two key matters raised by the OND or other matters raised by the DOP1, the OND and/or the FDA, that CTI's interpretation of the guidance provided by the OND, the DOP1 and/or the FDA may be different than the intent of the OND, the DOP1 and/or the FDA, that the OND, the DOP1 and/or the FDA may change its guidance, that the PIX301 study may not be deemed successful, that upon a re-review and/or resubmission of the NDA the FDA may find pixantrone to not be safe and/or effective, that the PIX301 study may still be deemed to be a failed study, that the FDA may require an additional clinical trial of pixantrone, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that CTI may not be able to provide satisfactory information in response to the CRL, that the FDA may not complete the review of the NDA by the PDUFA goal date of April 24, 2012, that the CHMP may not render an opinion on CTI's application for pixantrone with the EMA by January 19, 2012, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com

Investors Contact:
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
2. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
3. April 16th Congressional Hearing on Hospital Infections
4. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
7. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
8. Stryker to Host Conference Call on April 20, 2010
9. FDA Consumer Health Information - Generic Drug Roundup: April 2010
10. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
11. CardioGenics to be Spotlighted in Three Publications During Month of April
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... announced the appointment of Joann V. Lofgren ... Market Development, effective July 6, 2015. In this role, ... executing on the company,s market and product development strategy ... to welcome Joann to the OncoSec team and have ...
(Date:7/5/2015)... TOKYO , July 6, 2015 ... first international symposium on Medical-Engineering Collaboration "Medicine ... on July 10, 2015 in Tokyo, ... or its medical applied research will present their ... technology and a new industry produced with 8K ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... MATEO, Calif., Feb. 28, 2011 Nile Therapeutics, Inc. ... the development of novel therapeutics for heart failure patients, ... MDT ) on the clinical development of ... failure and renal disease applications. "We are ...
... 2011 Hotspur Technologies announced today that Dr. ... clinical use of its Keeper™ Embolectomy Catheter.  The ... within arteries, while also incorporating the capability of ... The Keeper Catheter combines a compliant ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... 100% of all acids, chemicals and impurities; it also properly mineralizes the water ... it contains harmful contaminants.  These harmful contaminants are a byproduct of how the ...
(Date:7/6/2015)... ... July 06, 2015 , ... In ... medicine, the American Orthopaedic Society for Sports Medicine ( AOSSM ) will present ... Orlando, FL. As a leader in orthopaedic sports medicine, AOSSM annually provides ...
(Date:7/6/2015)... ... 06, 2015 , ... Acara Partners, a leading business team ... its complimentary educational webinar series for the summer of 2015. ... their clients through targeted marketing, sales, digital communications, branding and business development programs. ...
(Date:7/6/2015)... ... ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value of more ... of over 3.2 percent in the years to come to hit the USD 6.9 ... an anticipated launch of a number of promising pipeline candidates and an increase in ...
(Date:7/6/2015)... ... ... doTERRA, the leading global essential oils company, is pleased to announce the ... position as Director of the Hinckley Institute at the University of Utah, a position ... states that he was ready for a new challenge, and out of many potential ...
Breaking Medicine News(10 mins):Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4
... CHICAGO, July 8 The Hispanic ... its 75 city tour, including the top 10,Hispanic cities, to ... The tour recently cruised through Chicago hosting free,events to encourage ... well,with nature,s wellness drink: milk. , ...
... ... Can Promote Prostate Health , ... Jacksonville, Fla. (Vocus) July 8, 2009 -- On June 30th, the ... effectiveness" research. Among the 100 different questions posed, high on the list was ...
... , WEDNESDAY, July 8 (HealthDay News) -- Though researchers aren,t ... longer, they hope a drug used to prevent rejection of ... , Middle-age mice that were given the drug rapamycin (Sirolimus) ... didn,t get the drug. , The findings, disclosed in a ...
... , WASHINGTON and EVANSTON, Ill., July 8 ... a data integration partnership facilitating integration of a ... SimCapture(R). SimCapture is an all-in-one solution for capturing, ... encounters. Mentice, manufacturer of the Mentice VIST(TM) endovascular ...
... patients rely on drugs to prevent graft rejection, ... The class of immunosuppressive drugs known as calcineurin ... patients, kidneys and lead to high blood pressure, ... can effectively replace calcineurin inhibitors in preventing graft ...
... SAN FRANCISCO, July 8 For the third ... one of the top medical groups in California as measured ... is the nation,s largest professional organization of physician groups practicing ... as being one of the best medical groups in California ...
Cached Medicine News:Health News:The Hispanic got milk? Campaign Visits Chicago from July 2 - July 10 2Health News:'Comparative Effectiveness' Research Addresses Options for Treating Prostate Cancer 2Health News:'Easter Island' Drug Adds Years to Mice 2Health News:B-Line Medical(R) and Mentice, Inc. Announce Data Integration Partnership 2Health News:B-Line Medical(R) and Mentice, Inc. Announce Data Integration Partnership 3Health News:Post-transplant combo can replace toxic immune-suppressing drugs in monkeys 2
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Medicine Products: